Can PRP Therapy Help Bone on Bone Knees: The KL-Grade Candidacy Framework That Gives You an Honest Answer

Introduction: Why ‘Bone on Bone’ Is Not a Single Diagnosis

Hearing the words “bone on bone” from an orthopedic surgeon can feel like a door slamming shut. Patients often leave that appointment believing their only options are to live with debilitating pain or undergo major surgery. The question of whether PRP therapy might offer an alternative deserves a thoughtful, honest answer.

Here is the reality that most content online fails to address: “bone on bone” is a colloquial term that actually spans a spectrum of severity. That spectrum determines everything about PRP candidacy, realistic outcomes, and even the specific formulation of PRP required to achieve results.

Rather than offering a blanket yes or no, this article uses the Kellgren-Lawrence (KL) grading system to provide a grade-specific answer. The difference between KL Grade 3 and true KL Grade 4 changes the entire conversation about whether PRP can help. Most online resources ignore this distinction entirely, leaving patients either falsely hopeful or unnecessarily discouraged.

This article covers what the KL grades mean, what the 2025 and 2026 clinical evidence actually says for each grade, why platelet concentration matters more than most patients realize, and what the honest roadmap looks like when PRP is not the right fit.

The scale of this problem is enormous. Knee osteoarthritis affects approximately 528 million people worldwide, including roughly 23% of adults over 40. The demand for honest, non-surgical guidance has never been greater.

Understanding the Kellgren-Lawrence Grading System: Your Self-Assessment Starting Point

The Kellgren-Lawrence (KL) system is the standard radiographic grading scale used by orthopedic physicians to classify knee osteoarthritis severity on a scale of 0 to 4. This grading is based on X-ray findings, specifically joint space narrowing, osteophyte (bone spur) formation, subchondral sclerosis (bone hardening), and bone deformity.

Patients can ask their doctor a simple question at their next visit: “What is my KL grade?” That single number is the most important factor in determining PRP candidacy.

Breaking Down Each KL Grade: What Your X-Ray Is Actually Telling You

KL Grade 0: No radiographic features of osteoarthritis. The joint space appears normal with no osteophytes present. PRP is not indicated at this stage.

KL Grade 1: Doubtful narrowing of joint space with possible osteophytic lipping. These are very early changes, and conservative management is the first-line approach.

KL Grade 2: Definite osteophytes with possible narrowing of joint space. This represents mild osteoarthritis. PRP has strong evidence at this stage. A 2026 five-year real-world study published in PLOS ONE confirmed durable long-term benefits of leukocyte-poor PRP in Grade I and II patients.

KL Grade 3: Multiple osteophytes, definite narrowing of joint space, some sclerosis, and possible deformity. This is moderate-to-severe osteoarthritis and represents the critical “candidacy threshold” where PRP evidence is strongest. Most clinical trials concentrate on this population.

KL Grade 4: Large osteophytes, marked narrowing of joint space, severe sclerosis, and definite deformity. This is true “bone on bone.” Cartilage is fully or nearly fully destroyed. This is where the honest conversation about PRP limitations must begin.

Many patients told they are “bone on bone” are actually KL Grade 3. This distinction dramatically changes their PRP outlook.

The Candidacy Threshold Concept: Why PRP Is Not a Binary Yes or No

The “candidacy threshold” serves as this article’s central framework. PRP is not simply appropriate or inappropriate for advanced knees; it is a grade-dependent, formulation-dependent decision.

The majority of clinical trials have excluded Grade 4 patients, creating a significant evidence gap specifically for bone-on-bone cases. This means most of the positive PRP data cited online does not directly apply to the most advanced patients.

Expert consensus supports a clear position: PRP injections are considered appropriate for patients up to KL Grade III after failed conservative treatment. PRP is not considered appropriate as a first treatment or in KL Grade IV cases.

This framing is not a dismissal of Grade 4 patients; it is an honest calibration of expectations. The question for Grade 4 is not “will PRP work like it does in Grade 3?” but rather “can PRP still provide meaningful benefit as part of a broader strategy?”

PRP for KL Grade 3 Knees: What the Evidence Actually Shows

Grade 3 represents the “sweet spot” for PRP therapy. Patients at this stage have significant cartilage loss and real pain, but enough remaining joint architecture for PRP’s growth factors to act upon.

A landmark 2025 meta-analysis published in the American Journal of Sports Medicine analyzed 1,995 patients and found PRP produced statistically and clinically superior improvement versus placebo at all follow-up points (1, 3, 6, and 12 months) when high-platelet PRP was used.

A separate 2025 meta-analysis examining 15 double-blind randomized controlled trials with 1,632 patients (KL Grade I through III) found PRP demonstrated significantly lower WOMAC pain scores and total scores versus hyaluronic acid at 12 months. Both improvements exceeded the minimal clinically important difference (MCID).

PRP consistently outperforms hyaluronic acid at 3, 6, and 12 months. Improvements are sustained at 12 to 24 months, representing a meaningful advantage over corticosteroids, which fade within months and may accelerate cartilage breakdown.

A 2025 comprehensive narrative review published in the Journal of Clinical Medicine synthesized 40 high-quality studies and concluded PRP is a “promising, safe, and well-tolerated option for early to moderate KOA.” Grade 3 falls squarely within this endorsed range.

The Grade 3 verdict: For patients with confirmed KL Grade 3 osteoarthritis who have tried and failed conservative treatments, high-platelet PRP is a clinically supported, evidence-backed option with a favorable risk-benefit profile. Patients seeking to understand the full non-surgical knee treatment options available at this stage will find PRP sits near the top of the evidence hierarchy.

PRP for True KL Grade 4 (Bone on Bone): An Honest Assessment

PRP cannot regenerate fully destroyed cartilage. Imaging studies, including the RESTORE trial published in JAMA in 2021, have not demonstrated cartilage regrowth with PRP. Emerging evidence only suggests it may slow cartilage loss progression.

The evidence gap must be addressed directly. The majority of clinical trials have excluded Grade 4 patients, so the robust positive data from Grade I through III studies cannot be extrapolated to true bone-on-bone cases.

One relevant randomized controlled trial (Joshi Jubert et al.) enrolled 75 patients with KL Grade 3 and 4 osteoarthritis. The study found a consistent trend favoring PRP over corticosteroids in pain, function, and patient satisfaction. However, differences did not reach statistical significance.

What PRP can still offer Grade 4 patients is meaningful pain relief and functional improvement, though the effect is less predictable and generally smaller than in earlier-stage disease.

For Grade 4 patients who have exhausted all non-surgical options and are not yet ready for surgery, PRP may serve as a legitimate pain management and surgery-delay strategy, even if it cannot reverse the structural damage.

Counterbalancing evidence deserves acknowledgment. Harvard Health Publishing and major societies including the ACR have noted that some well-designed clinical trials have not found PRP superior to placebo. The GRADE certainty of evidence for PRP in knee osteoarthritis is rated “moderate” as of 2025.

The Grade 4 verdict: PRP alone is unlikely to be the answer for true bone-on-bone knees, but it is not automatically off the table. The question is whether it is used strategically, with the right formulation, and ideally in combination with complementary biologics.

The Formulation Factor: Why Platelet Concentration Is the Single Biggest Predictor of Outcomes

Not all PRP is created equal. The platelet concentration in the final preparation varies dramatically depending on the centrifuge protocol, the machine used, and the provider’s technique.

The 2025 AJSM meta-analysis revealed a critical finding: high-platelet PRP (greater than 1,000,000 platelets per microliter) maintained benefits at 12 months, while low-platelet PRP (less than 1,000,000 platelets per microliter) failed to deliver meaningful pain relief at any timepoint.

A systematic review of 29 studies published in Arthroscopy confirmed dose-dependent efficacy. Studies with positive 12-month outcomes had an average platelet dose of approximately 5,464 × 10⁶ versus approximately 2,253 × 10⁶ in studies with no significant difference.

The leukocyte distinction also matters. Leukocyte-poor PRP (LP-PRP) is generally preferred over leukocyte-rich PRP (LR-PRP) for knee osteoarthritis. LR-PRP’s elevated pro-inflammatory cytokines may exacerbate joint inflammation rather than reduce it. The AOSSM confirms LP-PRP is associated with better IKDC scores than LR-PRP for knee osteoarthritis.

Practical guidance for patients: When evaluating a PRP provider, patients should ask specifically what platelet concentration the preparation achieves, whether LP-PRP or LR-PRP is used, and how concentration is verified. Understanding the full PRP injection procedure step by step can help patients ask the right questions before committing to a protocol.

If PRP is being considered for a Grade 4 patient, the formulation requirement becomes even more critical. A subtherapeutic preparation is unlikely to produce any meaningful benefit in the most advanced cases.

Injection Protocol Matters: Why One Shot Is Rarely Enough

Multiple injections are more effective than a single injection. Three PRP injections have been shown to be more effective than one in knee osteoarthritis, typically spaced 4 to 6 weeks apart.

A retrospective study published in Frontiers in Physiology analyzing 140 knee osteoarthritis patients found the number of injections was the strongest predictor of pain outcomes in multivariate analysis.

Sequential PRP treatments (2 to 3 sessions) can achieve results comparable to stem cell therapy, with better evidence and lower cost.

Precision-guided injection delivery using ultrasound or X-ray guidance is essential for accurate placement into the joint space, particularly in structurally compromised Grade 3 and 4 knees.

Patients should be skeptical of any provider offering a single PRP injection as a complete treatment for moderate-to-severe knee osteoarthritis.

The Grade-Dependent Treatment Framework: Matching the Right Strategy to Your KL Grade

Grade 1 and 2: High-platelet LP-PRP with standard conservative management offers excellent evidence for durable long-term benefit. Early intervention produces the best outcomes.

Grade 3: High-platelet LP-PRP (greater than 1,000,000 platelets per microliter) in 2 to 3 sessions, spaced 4 to 6 weeks apart. This grade has the strongest evidence base. PRP is appropriate after failed conservative treatment and may be combined with hyaluronic acid for synergistic benefit.

Grade 4 (true bone on bone): PRP alone is unlikely to be sufficient. Combination therapy with complementary biologics, such as BMAC (Bone Marrow Aspiration Concentrate) or hyaluronic acid, may offer greater benefit than PRP alone. Realistic goals are pain reduction and surgery delay, not cartilage regeneration.

BMAC contains mesenchymal stem cells and growth factors that may complement PRP’s anti-inflammatory effects in severely degenerated joints. The PRP plus hyaluronic acid combination may offer synergistic benefits, with hyaluronic acid providing viscosupplementation (joint lubrication) while PRP addresses the inflammatory and regenerative environment.

This framework is not a do-it-yourself decision. It requires a provider who can confirm the patient’s KL grade, assess individual modifying factors, and design a formulation-specific protocol.

Factors That Modify PRP Response: What Else Affects Candidacy

High BMI: Added mechanical stress on the joint reduces PRP efficacy and accelerates structural damage. Patients with high BMI may see diminished results regardless of grade.

Disease duration: Longer duration of osteoarthritis is associated with reduced PRP response. The Frontiers in Physiology study confirmed PRP is more effective in patients with shorter disease duration.

Age: While not an absolute contraindication, older patients with longer disease histories and greater comorbidities may have more variable responses. A detailed look at stem cell therapy age considerations provides useful context for how biological age interacts with regenerative treatment outcomes.

Medications: NSAIDs should be stopped approximately 7 days before PRP injection, as they can inhibit platelet function and reduce the efficacy of the preparation. Blood thinners also require management.

Hydration: Adequate hydration before the blood draw improves blood volume and may support platelet yield.

Baseline platelet health: Patients with certain blood disorders or very low baseline platelet counts may not be good candidates for PRP.

These factors mean that two patients with the same KL grade can have meaningfully different PRP outcomes. Personalized assessment is essential.

Addressing the Controversy: What the Skeptics Get Right (and Wrong)

The ACR and Arthritis Foundation currently recommend against PRP for knee osteoarthritis due to lack of standardization. Some well-designed trials, including the RESTORE trial published in JAMA in 2021, have not demonstrated PRP superiority over placebo.

However, the ACR position is increasingly at odds with accumulating evidence. The ACR guideline predates the 2024 and 2025 wave of high-quality Level I evidence, including the AJSM meta-analysis and multiple double-blind RCTs that specifically controlled for platelet concentration.

The core problem is this: most negative trials used low-platelet PRP formulations that the 2025 evidence now shows are ineffective. Comparing all PRP studies without accounting for platelet concentration is like comparing different doses of a medication and concluding the medication does not work.

The GRADE certainty of evidence is rated “moderate” as of 2025, reflecting genuine progress but also remaining uncertainty.

Honest bottom line: The skeptics are right that PRP is not a guaranteed solution and that standardization remains a critical gap. They are wrong to dismiss it categorically when high-platelet LP-PRP has demonstrated consistent, clinically meaningful benefits in well-designed trials.

Insurance, Cost, and Practical Realities: What Patients Need to Know Before Deciding

Medicare does not cover PRP for any orthopedic condition, including knee osteoarthritis, as confirmed by the CMS Local Coverage Determination (L39058).

Major private insurers, including Aetna, Cigna, United Healthcare, and Blue Cross Blue Shield, classify PRP as experimental or investigational and deny coverage. TRICARE ended provisional coverage in September 2024.

Cost reality: Patients pay out-of-pocket, averaging approximately $1,000 per injection nationally, with a range of $500 to $2,500 per session. A full 2 to 3 injection protocol may cost $2,000 to $7,500 total.

Regulatory context: PRP does not have FDA approval for knee osteoarthritis specifically; it is offered off-label in the U.S. Some PRP preparation devices have FDA clearance, but clearance is not the same as approval. As of 2026, the FDA has not approved PRP specifically for orthopedic conditions, though substantial clinical evidence supports safety and efficacy when administered by qualified providers within FDA regulatory frameworks.

Safety reassurance: PRP’s safety profile is favorable. The most common adverse events are transient post-injection pain flares and mild swelling resolving within days. No cases of septic arthritis were reported in large trials. No cartilage damage or tumorigenic effects have been observed.

Patients should factor in the full protocol cost (not just one injection), ask providers about their platelet concentration protocols, and weigh this against the cost and recovery burden of surgical alternatives.

If PRP Is Not the Right Fit: A Roadmap for What Comes Next

Patients need a clear roadmap, not a dead end.

For Grade 3 patients who do not respond adequately to PRP alone: Consider combination PRP plus hyaluronic acid, or escalate to BMAC therapy for a more potent regenerative stimulus. Understanding BMAC injection recovery time is an important part of planning this next step.

For Grade 4 patients who have tried PRP-based approaches without sufficient relief: Combination biologics (PRP plus BMAC) represent the next tier. Genicular nerve block or COOLIEF (cooled radiofrequency ablation) can provide pain management without addressing the structural issue.

Genicular Artery Embolization (GAE): This emerging procedure shows a 99.7% technical success rate with pain reduction of 34 to 39 points on the VAS. It represents a viable option for patients who are not surgical candidates.

Total knee arthroplasty (TKA): For true Grade 4 patients who have exhausted all non-surgical options, TKA remains the gold-standard long-term solution with well-established outcomes. PRP and biologics are best understood as tools to delay and potentially avoid surgery, not to replace it indefinitely when structural damage is complete. Patients weighing their options should review the full landscape of alternatives to knee replacement surgery before making a final decision.

Having a clear roadmap means no option is a failure. Each step provides information and relief while preserving future options.

How Unicorn Bioscience Approaches the KL-Grade Candidacy Framework

Unicorn Bioscience is a regenerative medicine practice that applies grade-specific, formulation-specific thinking of the kind described throughout this article.

The practice offers a multi-modal treatment menu including PRP, BMAC, exosome therapy, hyaluronic acid injections, and peptide therapy. This full spectrum of tools allows providers to match treatment to KL grade rather than applying a one-size-fits-all approach.

All injections are administered using ultrasound and X-ray guidance, ensuring accurate placement into the joint space. This precision is a critical factor for both efficacy and safety in structurally compromised knees.

Treatment protocols are developed based on individual patient factors including inflammation levels, age, injury type, current medications, and personal health goals. These are exactly the modifying factors discussed throughout this article.

Qualified candidates can receive same-day treatment, and virtual consultations are available for patients who want to discuss their KL grade and candidacy before committing to an in-person visit.

More than 90% of stem cell patients at Unicorn Bioscience have not gone on to knee replacement surgery. This outcome should be understood within the honest framework that results depend on grade, formulation, and protocol.

Locations span Texas (Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio), Florida (Boca Raton), and New York (Manhattan), making expert regenerative care accessible across multiple markets.

Contact: (737) 347-0446 or unicornbioscience.com.

Conclusion: The Honest Answer to Whether PRP Can Help Bone-on-Bone Knees

The honest answer to “can PRP therapy help bone-on-bone knees” is this: it depends on which grade of bone-on-bone the patient has, what formulation of PRP is used, and whether it is deployed as part of a strategic protocol or as a standalone injection.

The tiered verdict: Grade 3 patients receiving high-platelet LP-PRP in a multi-injection protocol have strong clinical evidence supporting meaningful, sustained improvement. Grade 4 patients face a more limited evidence base and should approach PRP as part of a combination strategy with realistic goals of pain reduction and surgery delay.

The single biggest predictor of PRP outcomes is platelet concentration. Greater than 1,000,000 platelets per microliter is the threshold that separates effective from ineffective preparations in the best available evidence.

Seeking honest, nuanced information before making a treatment decision is the right approach. The KL grading system gives every patient a concrete starting point for that conversation.

Knowing the KL grade, understanding what PRP can and cannot do at that grade, and working with a provider who matches formulation and protocol to the patient’s specific situation is how informed decisions are made, not by accepting a blanket yes or no.

Ready to Find Out If You Are a PRP Candidate? Start with a Personalized Consultation

The next step is scheduling a consultation to discuss the patient’s specific KL grade, imaging results, and treatment history. The goal of this consultation is to provide an honest, grade-specific answer, not to recommend a treatment that is not appropriate for the situation.

Virtual consultations are available for patients who want to start the conversation remotely before committing to an in-person visit. Qualified candidates can receive same-day treatment, reducing the barrier between consultation and care.

Call (737) 347-0446 or visit unicornbioscience.com to schedule a virtual or in-person consultation at any of the 8 locations across Texas, Florida, and New York.

Whether PRP is the right answer or a combination approach makes more sense, the first step is knowing exactly where the patient stands. That conversation starts here.